TW202342528A - 抗人類ｃｘｃｌ１抗體 - Google Patents

抗人類ｃｘｃｌ１抗體 Download PDF

Info

Publication number
TW202342528A
TW202342528A TW112103002A TW112103002A TW202342528A TW 202342528 A TW202342528 A TW 202342528A TW 112103002 A TW112103002 A TW 112103002A TW 112103002 A TW112103002 A TW 112103002A TW 202342528 A TW202342528 A TW 202342528A
Authority
TW
Taiwan
Prior art keywords
amino acid
human
antibody
acid sequences
cancer
Prior art date
Application number
TW112103002A
Other languages
English (en)
Chinese (zh)
Inventor
八代正和
山本百合恵
吉岡亜希子
中村康司
柳內浩之
井上俊和
Original Assignee
日商凱依歐姆 生物科學股份有限公司
公立大學法人大阪
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商凱依歐姆 生物科學股份有限公司, 公立大學法人大阪 filed Critical 日商凱依歐姆 生物科學股份有限公司
Publication of TW202342528A publication Critical patent/TW202342528A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW112103002A 2022-01-27 2023-01-30 抗人類ｃｘｃｌ１抗體 TW202342528A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-011107 2022-01-27
JP2022011107 2022-01-27

Publications (1)

Publication Number Publication Date
TW202342528A true TW202342528A (zh) 2023-11-01

Family

ID=87471580

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112103002A TW202342528A (zh) 2022-01-27 2023-01-30 抗人類ｃｘｃｌ１抗體

Country Status (10)

Country Link
US (1) US20250154240A1 (https=)
EP (1) EP4471057A4 (https=)
JP (1) JPWO2023145844A1 (https=)
KR (1) KR20240137027A (https=)
CN (1) CN118591554A (https=)
AU (1) AU2023213334A1 (https=)
CA (1) CA3249959A1 (https=)
IL (1) IL314512A (https=)
TW (1) TW202342528A (https=)
WO (1) WO2023145844A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026060413A1 (en) * 2024-09-16 2026-03-19 Calgent Biotechnology Co., Ltd. Single chain antibodies and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
KR20160021125A (ko) * 2013-05-17 2016-02-24 쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스) 항-cxcl1, cxcl7 및 cxcl8 항체 및 이들의 용도
EP3138903B1 (en) 2014-05-02 2022-02-09 Chiome Bioscience Inc. Cells for producing human antibody
JP6932365B2 (ja) * 2015-05-14 2021-09-08 公立大学法人大阪 スキルス性胃癌の治療剤、及び胃癌の予後の予測方法
EP3917949A4 (en) * 2019-01-28 2022-11-23 Charles J. Rosser COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS RELATED TO CXCL1 FUNCTION
JP7471156B2 (ja) 2020-06-29 2024-04-19 ギガフォトン株式会社 極端紫外光集光ミラー及び電子デバイスの製造方法

Also Published As

Publication number Publication date
EP4471057A4 (en) 2026-03-04
IL314512A (en) 2024-09-01
US20250154240A1 (en) 2025-05-15
CN118591554A (zh) 2024-09-03
JPWO2023145844A1 (https=) 2023-08-03
KR20240137027A (ko) 2024-09-19
CA3249959A1 (en) 2025-06-17
WO2023145844A1 (ja) 2023-08-03
AU2023213334A1 (en) 2024-09-05
EP4471057A1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
US20240084010A1 (en) Bispecific anti-cd3 antibodies, bispecific activatable anti-cd3 antibodies, and methods of using the same
CN114514246B (zh) 对nectin-4具有特异性的抗体及其用途
CA3027417C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
US11498972B2 (en) Anti-OX40 antibody and use thereof
CA2798778C (en) Anti-human trop-2 antibody having anti-tumor activity in vivo
TWI564306B (zh) 雙特異性抗體
JP2021501120A (ja) 抗ガレクチン−９抗体及びその使用
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
NZ724649A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
KR102019032B1 (ko) CD66c에 특이적으로 결합하는 항체 및 그의 용도
KR20140027051A (ko) 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
WO2022068810A1 (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
CN113164777A (zh) Csf1r/ccr2多特异性抗体
TW202214694A (zh) 結合ｔｎｆｒ２的抗體及其用途
WO2022194201A1 (zh) 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
TW202342528A (zh) 抗人類ｃｘｃｌ１抗體
TWI862019B (zh) 治療性ｃｄ２４人類化單株抗體及抗腫瘤轉譯應用
US20240101663A1 (en) Method for inhibiting tumour cell growth based on ccdc112
KR102451588B1 (ko) Prl3 항체
TW202340250A (zh) 標靶ｃｄ２５的抗體及其製備方法和應用
WO2023190465A1 (ja) 抗ヒトｓｅｍａ７ａ抗体
CN121008043A (zh) Axl-gas6复合物的检测方法及在心肌梗死患者中的应用
KR20250001497A (ko) 항-cxcr2 항체 및 이의 용도
HK40006061B (en) Prl3 antibody
HK40006061A (en) Prl3 antibody